This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1 · go to the accepted answer.
Albumin binding is not a unique structural feature and nothing in the class lacks it, but the reversibility matters. Semaglutide binds albumin covalently through a fatty side chain, which creates a very long half-life at the cost of sequestering the free form. That is a trade-off and it is the trade-off that allows weekly dosing.
Marking that as an opinion rather than a finding.
Semaglutide versus liraglutide in STEP 8: semaglutide produced greater weight reduction and the discontinuation rates differed. But the trial was open-label for the dosing schedule, which admits expectation effects. Weekly versus daily itself is part of the comparison, not a confounding variable to be removed.
I would put the burden of proof on the interesting explanation, not the dull one.
I have been on both sides of the published dose-response for semaglutide argument in this category within eighteen months, which should tell you how strong the evidence for either side is.
On post #91 — agreed on the reasoning, with one qualification.
Published dose-response for semaglutide: I have looked for the primary source twice and failed twice. Either it does not exist or it is somewhere I do not know to look, and I would like to know which.
The C-cell question: semaglutide triggered medullary thyroid carcinoma in rodent toxicology studies. A signal in rodents does not automatically appear in humans, but it is the reason the compound is contraindicated in people with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.
Discontinuation rates in the trials are worth reading alongside efficacy and almost never are. A large mean effect in a population where a meaningful fraction stopped early is telling you two things, not one.
A single observation, in a thread that deserves better than single observations.
Narrowing post #99, because the general version has more than one answer.
Is there a ceiling dose beyond which the effect plateaus? The trials did not study that because they stopped at 2.4 mg. Some people report trying higher doses, but trial data is absent and off-label dosing enters territory this site does not advise on.
Published dose-response for semaglutide is a question about a distribution, not about a value, and treating it as a value is what produces the confident wrong answers.
Narrowing post #99, because the general version has more than one answer.
On identity confirmation: a mass close to 4113.6 Da on the intact molecule is consistent with semaglutide and is also consistent with several closely related species. Mass narrows the field; it does not close it, and no certificate should be read as though it did.
Post #99 put the caveat in the right place and I want to underline it.
The most useful reply I ever got about published dose-response for semaglutide was a request to state my units. It sounds like pedantry and it has saved me twice.
The honest answer on published dose-response for semaglutide is that it depends, and the useful part is the list of what it depends on. Four items, in rough order of how much they matter.
Most people get the first two right and then argue about the fourth.
The opalescent appearance in semaglutide solutions is occasionally noted and the mechanism is unclear. It does not appear to correlate with product failure in practice. Visible particles or frank cloudiness is different and would be reason to contact the supplier.
Where I part company with post #103, and it is a narrow parting.
I read the earlier replies on published dose-response for semaglutide twice before writing this, because I had assumed the opposite and wanted to be sure I was disagreeing with what was said rather than what I expected.
Post #107 is the version of this I will quote in future. One addition.
Published dose-response for semaglutide came up in a thread eighteen months ago and was answered well. I cannot find it, which is itself the problem, so here is the reconstruction.
On alcohol: the labelling does not contraindicate it, but it raises gastric irritation risk and semaglutide already does that. There is no published interaction study and the conservative position is to limit it if you are titrating or if gastrointestinal symptoms are troublesome.
I would hold that lightly until someone with a larger sample weighs in.
Appetite effects and gastrointestinal effects are frequently reported together and are not the same mechanism reported twice. Slowed gastric emptying contributes to both, but central satiety signalling accounts for effects that persist after emptying has normalised.
That is the practical version. The rigorous version is longer and says the same thing.
Distinguishing three things in the published dose-response for semaglutide discussion that keep getting used interchangeably: the observation, the proposed mechanism, and the recommendation that gets attached to both.
Semaglutide's structure is a modified backbone with a C18 diacid attached through a spacer. The acylation is the reason for the long half-life and it is also the reason a plain sequence comparison against native GLP-1 is misleading about how the molecule behaves.
Filing this under things that are true until someone shows me otherwise.
On formulation: the licensed product is buffered and includes a preservative in the multi-dose presentation. A reconstituted research preparation matches neither, and stability claims made about the first do not carry over to the second.
It took me longer than it should have to see that.
The 165 to 184 hour half-life range gets quoted as a fixed number. It is a range across a studied population, and individual clearance varies enough that a person's own steady state may be reached earlier or later than the population average implies.
I would rather be precise about what I do not know than vague about what I do.
Post #116 describes the usual case. This is about the unusual one.
Having read the whole published dose-response for semaglutide thread before replying: the question in the first post has not actually been answered yet, and three of us have answered a nearby one instead.
Injection site does not appear to matter much for semaglutide exposure. The published comparisons of abdomen, thigh and upper arm found differences small enough to be clinically unimportant, which is not true of every injectable.
I have changed my mind on this once already, so take it as current rather than settled.
On identity confirmation: a mass close to 4113.6 Da on the intact molecule is consistent with semaglutide and is also consistent with several closely related species. Mass narrows the field; it does not close it, and no certificate should be read as though it did.
Not a strong opinion, just a consistent one.